The Study for Efficacy of Adalimumab Conbined Elemental Diet Therapy for Crohn's Disease

The Study for Efficacy of Adalimumab Conbined Elemental Diet Therapy for Crohn's Disease - The Efficacy of Adalimumab

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005762

Enrollment

Registered

2011-06-13

Start date

2010-10-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

1)Adalimumab (HUMIRA 40mg for SC Injection) Inject SC 160mg on Day 1, then inject SC 80 mg on Day 15, and inject SC 40 mg every other week, beginning on Day 29. 2)Elental(1 kcal/ml

80g/300ml)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Crohn's Disease patient who was ineffective for present therapy and who has not been treated with anti TNF alpha antibody.

Exclusion criteria

Exclusion criteria: 1)The patient who has internal fistula 2)The patient who is planning to have an operation 3)The patient who is short bowel syndorome 4)The patient of contraindication for adalimumab or Elental 5)The case which is hard to get the patient's consent 6)The patient who was judged for unsuitable by responsibility doctor

Design outcomes

Primary

Measure	Time frame
CDAI score in the 28th week (the rate of remission, CR70, CR100), SF-36, IBDQ	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

The Study for Efficacy of Adalimumab Conbined Elemental Diet Therapy for Crohn&#39;s Disease